Clinical Trials
3 trialsNCT03280160 2022-09-16
Protocol GELLC-7: Ibrutinib Followed by Ibrutinib Consolidation in Combination With Ofatumumab
PETHEMA Foundation
Phase 2 Unknown
NCT01678430 2012-10-15
RIAltO
University of Liverpool
Phase 3 Unknown
NCT01221103 2011-09-13
Dexamethasone, Ofatumumab and Bendamustine (DOT) First-line in Mantle-cell Lymphoma(MCL)
Southern Europe New Drug Organization
Phase 1/2 Unknown